AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain ...

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

The global cardiac amyloidosis market is poised for substantial growth, driven by rising prevalence and awareness of amyloidosis-related cardiac conditions. Characterized by amyloid protein deposition ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

The AI model effectively spotted all subtypes of amyloidosis in the dataset, with an area under the receiver-operating characteristic curve (AUROC) of 0.93, a sensitivity of 85% for identifying ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

A new AI model accurately detected cardiac amyloidosis from echocardiograms with higher accuracy vs. other amyloidosis risk ...

Anselamimab is an anti-fibril monoclonal antibody designed to reduce or eliminate amyloid deposits by binding with targets of amino acids on misfolded amyloid fibrils.

So, amyloidosis, there are several types, several causes, and several symptoms, so you need a comprehensive team to get together and put this puzzle together. Interviewer: Yeah, and we have a clinic ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...